DICE Therapeutics, Inc.

NasdaqGM:DICE Stock Report

Market Cap: US$2.3b

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

DICE Therapeutics Past Earnings Performance

Past criteria checks 0/6

DICE Therapeutics's earnings have been declining at an average annual rate of -51%, while the Pharmaceuticals industry saw earnings growing at 16% annually.

Key information

-51.03%

Earnings growth rate

48.63%

EPS growth rate

Pharmaceuticals Industry Growth5.95%
Revenue growth raten/a
Return on equity-20.08%
Net Marginn/a
Last Earnings Update30 Jun 2023

Recent past performance updates

Recent updates

Analysis Article • May 14

We're Not Very Worried About DICE Therapeutics' (NASDAQ:DICE) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. Indeed, DICE Therapeutics...
Seeking Alpha • Oct 11

DICE Therapeutics positive phase 1 data for psoriasis candidate leads shares 71% higher

Top-line results from a phase 1 trial of DICE Therapeutics' (NASDAQ:DICE) DC-806 for psoriasis showed the candidate met its proof-of-concept goal and was biologically active. Shares are up 71% in premarket trading. Data also showed DC-806 was well tolerated with an excellent safety profile. The placebo-controlled portion enrolled eight psoriasis patients in the high dose group (800 mg BID), 13 patients in the low dose group (200 mg BID), and 11 patients in the placebo group. After four weeks of treatment, the mean percentage reduction in Psoriasis Area and Severity Index from baseline was 43.7% in the high dose group compared to 13.3% in the placebo group. DICE (DICE) now plans to move DC-806, an oral IL-17 antagonist, into a dose-ranging phase 2b clinical trial. The company anticipates submitting an IND application with the US FDA in 1H 2023 and begin phase 2b at that time. Seeking Alpha's Quant Rating views DICE as a hold with high marks for growth and momentum.
Analysis Article • Sep 11

Here's Why We're Not Too Worried About DICE Therapeutics' (NASDAQ:DICE) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Aug 11

DICE Therapeutics GAAP EPS of -$0.58

DICE Therapeutics press release (NASDAQ:DICE): Q2 GAAP EPS of -$0.58. Cash, cash equivalents and marketable securities totaled $282.2 million at June 30, 2022. The Company expects its current cash position to fund operations through mid-2024 and expected key clinical milestones.
Seeking Alpha • Jul 18

DICE Therapeutics initiated at buy at Wainwright on platform for small molecule drugs

HC Wainwright has initiated coverage of DICE Therapeutics (NASDAQ:DICE) with a buy rating lauding the company's DELSCAPE technology platform aimed at creating new therapies against "difficult to target protein-protein interactions (PPIs), using small, targeted DNA-enabling libraries (DELs)." The firm has a $40 price target (~151% upside based on Friday's close). Analyst Emily Bodnar said that DELSCAPE can "identify selective binders by producing small, targeted DELs which has led to hundreds to tens of thousands of hits against difficult PPI targets." The company's lead candidate DC-806, a pill that targets IL-17, is being eyed for psoriasis. It is currently in phase 1. Bodnar conceded that although there are several IL-17-targeted biologics for psoriasis and related indications, there is only one approved that is a pill, Amgen's (AMGN) Otezla (apremilast). She noted that though Otezla has a PASI-75 score (efficacy) of only ~30%, the drug has more than $2B in annual sales. A full data readout from the phase 1 trial is expected this quarter, and if it is positive, the stock could see significant upside, Bodnar wrote.

Revenue & Expenses Breakdown

How DICE Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NasdaqGM:DICE Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 230-1043224
31 Mar 230-91280
31 Dec 220-84260
30 Sep 220-77230
30 Jun 220-74210
31 Mar 221-59160
31 Dec 211-49120
30 Sep 211-4090
30 Jun 212-2970
31 Mar 211-2750
31 Dec 201-2450
31 Dec 196-1340

Quality Earnings: DICE is currently unprofitable.

Growing Profit Margin: DICE is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: DICE is unprofitable, and losses have increased over the past 5 years at a rate of 51% per year.

Accelerating Growth: Unable to compare DICE's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: DICE is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-16.4%).

Return on Equity

High ROE: DICE has a negative Return on Equity (-20.08%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/08/10 05:39
End of Day Share Price 2023/08/08 00:00
Earnings2023/06/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

DICE Therapeutics, Inc. is covered by 12 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jason Matthew GerberryBofA Global Research
Edward NashCanaccord Genuity
Prakhar AgrawalCantor Fitzgerald & Co.